BIOGEN Engage study


This is a Clinical Research Study trying to find out if a new drug called Aducanumab is able ‘to target and reduce harmful amyloid plaques (abnormal deposits) that form in the brains of people with Alzheimer’s Disease’. 

Who can take part?

We are looking for people between the ages of 50-85 who are experiencing problems with memory or thinking clearly. They need to have a diagnosis of Mild Cognitive Impairment or be willing to see Dr Coulthard in the Mild Cognitive Impairment Clinic. 

What will happen to me if I take part?

Potential participants will need to attend three screening visits to find out whether they are eligible to take part. They will have blood taken, physical and memory assessments and different types of scan of the head. Anyone who is eligible to enter the study will then come to the Bristol Brain Centre and have monthly intravenous infusions and more physical and memory assessments over an eighteen month period.  For further information, please contact the ReMemBr Group.

Futher information is available at the following links: